MBX Biosciences Inc Dossier - Source-backed chat

MBX Biosciences Inc

MBXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.43

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $56.55Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.7B

Enterprise Value $2.7B

Shares Outstanding 50.2M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MBX Biosciences is a clinical-stage biopharmaceutical company leveraging its proprietary Precision Endocrine Peptide (PEP) platform to develop long-acting, highly stable peptide therapeutics. The company's lead asset, canvuparatide (MBX 2109), is poised to enter a pivotal Phase 3 trial in Q3 2026 for chronic hypoparathyroidism, backed by strong Phase 2 Avail trial data and a successful FDA End-of-Phase 2 meeting. Furthermore, MBX is rapidly expanding its metabolic footprint with MBX 4291, a once-monthly GLP-1/GIP co-agonist prodrug for obesity, with key Phase 1 data expected in Q4 2026. Supported by a robust cash position of $440 million (runway extending into 2029), MBX is well-capitalized to achieve major clinical de-risking milestones without near-term dilution risk.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$70.00

Mean target$88.40

High · most bullish analyst$121.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$70.00

The Phase 3 trial for canvuparatide experiences significant enrollment delays or clinical holds, allowing competitors (such as AstraZeneca/Amolyt) to capture the chronic hypoparathyroidism market share. Additionally, MBX 4291's Phase 1 MAD data in Q4 2026 reveals safety or tolerability issues (e.g., severe gastrointestinal side effects) that undermine its once-monthly dosing thesis, forcing a costly redesign or termination of the program. R&D expenses escalate rapidly, shortening the cash runway.

Base CaseCentral scenario

$88.40

Matches the consensus mean

MBX successfully initiates the Phase 3 trial for canvuparatide in Q3 2026 and maintains its clinical timeline. MBX 4291 Phase 1 MAD data in Q4 2026 supports once-monthly dosing with a competitive tolerability profile. The company continues to execute on its obesity pipeline expansion, nominating its amycretin and triple-agonist candidates. The cash runway remains secure into 2029, and the stock moves steadily upward as clinical milestones are met, aligning with consensus Wall Street expectations.

Bull CaseUpside scenario

$121.00

Canvuparatide successfully initiates and rapidly enrolls its Phase 3 trial, demonstrating best-in-class efficacy (calcium normalization and independence from conventional therapy) with a convenient once-weekly dosing profile. Simultaneously, MBX 4291's Phase 1 MAD data in Q4 2026 confirms strong tolerability and a clear pharmacokinetic profile supporting once-monthly dosing, positioning MBX as a highly disruptive player in the massive metabolic/obesity market. Preclinical candidates (amycretin and triple-agonist prodrugs) advance smoothly into IND-enabling studies, attracting lucrative big pharma collaboration interest.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary PEP platform designed to overcome the short half-life and high peak-to-trough ratios of native peptide therapies, enabling once-weekly or once-monthly dosing.
Strong Phase 2 data for lead asset canvuparatide, showing sustained benefit, calcium normalization, and high patient retention in the open-label extension.
Robust balance sheet with $440 million in cash and investments as of Q1 2026, providing a clear operational runway into 2029.
High-potential metabolic pipeline led by MBX 4291, targeting the multi-billion dollar obesity market with a highly differentiated once-monthly dosing profile.

Key Investment Risks

Clinical-stage risk: The company has no approved products and no commercial revenues, making it entirely dependent on clinical trial success.
Intense competition in the endocrine and metabolic spaces, particularly from established pharmaceutical giants and advanced clinical peers.
Execution risk associated with scaling up manufacturing and clinical operations for the upcoming Phase 3 canvuparatide trial.

Thesis Invalidation Triggers

Failure to initiate the Phase 3 canvuparatide trial by the end of 2026.
Phase 1 MAD data for MBX 4291 showing poor tolerability or failing to support once-monthly dosing.
A material safety signal or clinical hold imposed by the FDA on any of the lead clinical programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.